Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy.
about
Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectivesApoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis.Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trialsClinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer.Treatment of resectable gastric cancer.Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer.Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites.Adjuvant and preoperative therapy for localized gastric cancer.Questionnaire survey regarding the current status of super-extended lymph node dissection in Japan.Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases.Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases.Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge!R0 resection in the treatment of gastric cancer: room for improvement.Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy.Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report.Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer.Factors predicting peritoneal recurrence in advanced gastric cancer: implication for adjuvant intraperitoneal chemotherapy.Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis.
P2860
Q26774283-23C8A55E-5F18-4172-B3B5-4E54F6E9F95EQ34012672-51ADD555-E468-4937-8D37-8AF652F55816Q34015030-96F7DF61-DA75-4092-8ABD-FCD936031B96Q35002601-14192BBA-AAD6-49B3-BA97-9938DF2AADA3Q35059969-12D74389-3D5F-4B4F-ADE4-7368FCFC7AE4Q35477684-CF138AA5-DBCD-45A1-9322-853397DFAB6FQ35688584-CDAA4F6B-E285-4A30-A561-8FA43FEFCA9AQ36151519-0A6D3E13-A85E-44D7-AB6C-3D449D8E24F7Q36628679-A1AA7F58-80E2-4B0A-B2DB-FD20181377F7Q37076527-BBE6E416-1B2C-4956-AFFA-A1C29A459278Q37263118-B925598D-AF0E-4959-80C3-0E13F2CBA344Q38198011-30FFD923-28FA-4CEF-98E0-282DBD3B4008Q41099259-8C4F9962-496E-4366-BC91-9EA3787DFC6AQ42718832-A24C6A97-D72F-4DC9-87B7-558250F298D8Q42732352-D9783EEF-3BAA-4646-A6F0-8542C49A3618Q43958960-AC7BB97A-1BDA-4401-BFAD-D79189DEB323Q44476207-9F51B7CA-D00D-43FF-B2E7-9A2A9D9C802AQ45306704-82521B0F-569D-4F2C-B3F0-5C617BF47431Q46066281-BFB33D13-0667-45C9-8C77-84E1DD511A54Q53096881-3CC304AC-0F58-4773-A8F8-740A489FE610
P2860
Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Resectable gastric carcinoma. ...... nd postoperative chemotherapy.
@en
Resectable gastric carcinoma. ...... nd postoperative chemotherapy.
@nl
type
label
Resectable gastric carcinoma. ...... nd postoperative chemotherapy.
@en
Resectable gastric carcinoma. ...... nd postoperative chemotherapy.
@nl
prefLabel
Resectable gastric carcinoma. ...... nd postoperative chemotherapy.
@en
Resectable gastric carcinoma. ...... nd postoperative chemotherapy.
@nl
P2093
P1433
P1476
Resectable gastric carcinoma. ...... nd postoperative chemotherapy.
@en
P2093
Jackson DE
P304
P356
10.1002/1097-0142(19911001)68:7<1501::AID-CNCR2820680706>3.0.CO;2-L
P407
P577
1991-10-01T00:00:00Z